Truist Securities Downgrades Amgen to Hold, Raises Price Target to $333

Benzinga · 10/14 13:56
Truist Securities analyst Robyn Karnauskas downgrades Amgen (NASDAQ:AMGN) from Buy to Hold and raises the price target from $320 to $333.